

# JOURNAL OF CLINICAL RESEARCH BEST PRACTICES

Vol. 6, No. 2, February 2010

"Can You Handle the Truth?"

## "PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2009/2010"

Mark P. Mathieu, editor, 2009, 319 pages, PAREXEL International, \$425.00

Review by Norman M. Goldfarb

"PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2009/2010" is the industry's most complete source of statistics and other facts about drug development. It's hard to imagine how anyone could understand current trends in drug development without this book.

This book has been selected for  
[The First Clinical Research Bookshelf](#)  
Essential reading for clinical research professionals

The book includes hundreds of charts, tables, figures and analyses in five sections:

- R&D Spending
- Products in Development
- Drug Development Costs/Complexity, Development Time, and Success Rates
- Regulatory/FDA Statistics
- International Statistics

A few of the fascinating findings in the book include:

- In 2008, nine biopharmaceutical companies (Pfizer (including Wyeth), Roche (including Genentech), Merck & Co. (including Schering-Plough), Novartis, Sanofi-Aventis, GlaxoSmithKline, Johnson & Johnson, AstraZeneca and Bristol-Myers-Squibb) accounted for half of the industry's total R&D spending.
- The complexity of clinical trials (as measured by the number of procedures per subject) declined by 22% from 2008 to 2006. The average complexity of trials in Asia is only 64% that of trials in the U.S.
- The average number of study subjects per submitted New Drug Application (NDA) declined 61% from 5,400 in 1999 to 2,100 in 2007.
- The probability of a successful NDA for a new active substance from first-in-man trials is 29% in anti-infectives, roughly three times the probability for anti-cancer, cardiovascular and nervous-system drugs.

The book is available at <http://www.barnettinternational.com/>.

### Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or [ngoldfarb@firstclinical.com](mailto:ngoldfarb@firstclinical.com).